Abstract: Disclosed are compositions, methods, and kits for treating conditions including; ameliorating side effects associated with compounds such as lipase inhibitors; gastrointestinal distress; fecal urgency; obesity; hyperlipidemia; diarrhea; reducing levels of toxic substances; reducing blood cholesterol levels; inducing satiety; effecting weight loss; effecting weight control; and treating, delaying onset and/or preventing Type II diabetes. One embodiment includes compositions for administration to an animal for stiffening lipophilic substances in the gastrointestinal tract. Such stiffening agents have a complete melting point of about 33° C. or greater. Kits comprising the composition are also included. Methods of stiffening lipophilic substances present in the gastrointestinal tract of an animal are also provided. The methods comprise administering a composition comprising a safe and effective amount of a stiffening agent to an animal.

Abstract: The present invention is for compositions and methods for managing the body weight of a subject using said compositions. Weight management, particularly weight gain and loss, is effectuated by producing a sensation of satiety in said subjects. The method of managing body weight includes administering the composition prior to food consumption, concurrent with food consumption, as replacement for food consumption and combinations thereof.

Abstract: The use of sucrose polyester containing behenate fatty acid chains as a non-absorbable fat marker to determine total dietary fat absorption by the digestive tract of a subject. A test food for use in measuring fat absorption contains a non-absorbable fat and a dietary fat. The method is useful for diagnostic testing for diagnosing malabsorption of dietary fat by the digestive tract of the subject, and impairment of dietary fat digestion in the subject.

Abstract: The present invention is for compositions and methods for managing the body weight of a subject using said compositions. Weight management, particularly weight gain and loss, is effectuated by producing a sensation of satiety in said subjects. The method of managing body weight includes administering the composition prior to food consumption, concurrent with food consumption, as replacement for food consumption and combinations thereof.

Abstract: This disclosure relates to compositions suitable for a variety of treatments, including ameliorating the undesirable side effects associated with compounds such as lipase inhibitors (e.g., anal leakage of undigested fat or oil). In particular, one embodiment of the present invention relates to compositions that are suitable for administration to an animal for the purpose of stiffening one or more lipophilic substances present in the gastrointestinal tract of the animal. The stiffening agents have a complete melting point of about 33° C. or greater. Various kits comprising the compositions are also described herein.

Abstract: This disclosure relates to compositions comprising an open-celled polymeric foam wherein the compositions are useful for sequestering lipophilic materials present in the gastrointestinal tract, thereby inhibiting the absorption of such lipophilic materials by the body. The disclosure further relates to compositions comprising the open-celled polymeric foam wherein the compositions are useful for ameliorating side effects associated with the use of lipase inhibitors. In a preferred embodiment, this disclosure relates to compositions comprising polymeric foam materials made from high internal phase emulsions, where such foams are useful for sequestering lipophilic materials. Further disclosed are compositions comprising open-celled polymeric foams wherein the compositions are useful for the purpose of sequestering aqueous and/or hydrophilic materials present in the gastrointestinal tract, thereby ameliorating diarrhea.

Abstract: This disclosure relates to compositions comprising an open-celled polymeric foam wherein the compositions are useful for sequestering lipophilic materials present in the gastrointestinal tract, thereby inhibiting the absorption of such lipophilic materials by the body. The disclosure further relates to compositions comprising the open-celled polymeric foam wherein the compositions are useful for ameliorating side effects associated with the use of lipase inhibitors. In a preferred embodiment, this disclosure relates to compositions comprising polymeric foam materials made from high internal phase emulsions, where such foams are useful for sequestering lipophilic materials. Further disclosed are compositions comprising open-celled polymeric foams wherein the compositions are useful for the purpose of sequestering aqueous and/or hydrophilic materials present in the gastrointestinal tract, thereby ameliorating diarrhea.

Abstract: This disclosure relates to compositions comprising an open-celled polymeric foam wherein the compositions are useful for sequestering lipophilic materials present in the gastrointestinal tract, thereby inhibiting the absorption of such lipophilic materials by the body. The disclosure further relates to compositions comprising the open-celled polymeric foam wherein the compositions are useful for ameliorating side effects associated with the use of lipase inhibitors. In a preferred embodiment, this disclosure relates to compositions comprising polymeric foam materials made from high internal phase emulsions, where such foams are useful for sequestering lipophilic materials. Further disclosed are compositions comprising open-celled polymeric foams wherein the compositions are useful for the purpose of sequestering aqueous and/or hydrophilic materials present in the gastrointestinal tract, thereby ameliorating diarrhea.

Abstract: Anti-anal leakage agents are used in combination with liquid polyol fatty acid polyesters to provide pharmaceutical and food compositions for treating and/or preventing hypercholesterolemia while avoiding undesired anal leakage of the liquid polyesters.

Abstract: Anti-anal leakage agents are used in combination with vitamin-fortified liquid fatty acid polyester compositions to provide pharmaceutical and food compositions for treating and/or preventing hypercholesterolemia while avoiding undesired anal leakage of the polyesters.